Menu Search
Equities

Frontage Holdings Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1521:HKG.HZ

Frontage Holdings Corp

Actions
  • Price (HKD)1.08
  • Today's Change0.00 / 0.00%
  • Shares traded2.00k
  • 1 Year change-27.52%
  • Beta1.0036
Data delayed at least 15 minutes, as of Feb 16 2026 03:40 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Frontage Holdings Corporation is a holding company. It provides laboratory and related services to pharmaceutical and agrochemical companies, as well as bioequivalence clinical and chemical services. The Company has two main divisions: Global Laboratory Services and Global Drug Discovery & Development Services. The Global Laboratory Services division offers laboratory testing support for clients involved in drug development. The Global Drug Discovery & Development Services division includes Drug Development Unit, the Drug Discovery Unit, and the Pharmaceutical Product Development Unit. Its Global Laboratory Services encompass regulated and non-regulated bioanalysis (both small and large molecules), biomarkers, genomics, manufacturing and controls analytical testing, and central laboratory services. The Drug Development Unit includes drug metabolism and pharmacokinetics, Safety and Toxicology. The Company's segments include North America and Europe and PRC.

  • Revenue in HKD (TTM)1.98bn
  • Net income in HKD29.97m
  • Incorporated2018
  • Employees1.54k
  • Location
    Frontage Holdings Corp700 Pennsylvania DriveExton 19341-1129United StatesUSA
  • Phone+1 (610) 232-0100
  • Fax+1 (610) 232-0101
  • Websitehttps://www.frontagelab.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.